Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease

Ebola virus (EBOV) infections result in aggressive hemorrhagic fever in humans, with fatality rates reaching 90% and with no licensed specific therapeutics to treat ill patients. Advances over the past 5 years have firmly established monoclonal antibody (MAb)-based products as the most promising the...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Hualei, Wong, Gary, Zhu, Wenjun, He, Shihua, Zhao, Yongkun, Yan, Feihu, Rahim, Md Niaz, Bi, Yuhai, Zhang, Zirui, Cheng, Keding, Jin, Hongli, Cao, Zengguo, Zheng, Xuexing, Gai, Weiwei, Bai, Jieying, Chen, Weijin, Zou, Yong, Gao, Yuwei, Gao, George F., Yang, Songtao, Xia, Xianzhu, Qiu, Xiangguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2019
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384060/
https://www.ncbi.nlm.nih.gov/pubmed/30541860
http://dx.doi.org/10.1128/JVI.01548-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6384060/
https://www.ncbi.nlm.nih.gov/pubmed/30541860
http://dx.doi.org/10.1128/JVI.01548-18

Ejemplares similares